|
Manufacturing Concerns in CRL for Luitpold
The FDA has handed Luitpold Pharmaceuticals a Complete Response Letter (CRL) on its NDA for Injectafer after a recent inspection raised concerns about the drugmaker's Shirley, N.Y. manufacturing facility.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives